Validation Data Gallery
Tested Applications
Recommended dilution
| Application | Dilution |
|---|---|
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Product Information
86250-1-PBS targets Cytokeratin 19 in WB, IHC, IF/ICC, IF-P, FC (Intra), Indirect ELISA applications and shows reactivity with human samples.
| Tested Reactivity | human |
| Host / Isotype | Rabbit / IgG |
| Class | Recombinant |
| Type | Antibody |
| Immunogen |
Peptide 相同性解析による交差性が予測される生物種 |
| Full Name | keratin 19 |
| Calculated molecular weight | 44 kDa |
| Observed molecular weight | 44 kDa |
| GenBank accession number | BC002539 |
| Gene Symbol | Cytokeratin 19 |
| Gene ID (NCBI) | 3880 |
| Conjugate | Unconjugated |
| Form | |
| Form | Liquid |
| Purification Method | Protein A purification |
| UNIPROT ID | P08727 |
| Storage Buffer | PBS only{{ptg:BufferTemp}}7.3 |
| Storage Conditions | Store at -80°C. |
Background Information
Cytokeratin 19 (CK19 or KRT19) is a type I (acidic) cytokeratin. It is an intermediate filament protein providing structural rigidity and multipurpose scaffolds in epithelial cells. CK19 is often overexpressed in various cancers (e.g., hepatocellular carcinoma [HCC], pancreatic adenocarcinoma, lung cancer) and serves as a biomarker for hepatic progenitor cells (HPCs) associated with poor prognosis in HCC patients . Additionally, CK19 expression is common in pancreatic and gastrointestinal adenocarcinomasand has been studied as a potential diagnostic and prognostic marker for pancreatic neuroendocrine tumors (PNETs), where positive CK19 expression correlates with poor prognosis. Serum CK19 fragments (e.g., CYFRA 21-1, CK19-2G2) have been investigated as tumor markers for lung and breast cancer, with preoperative levels associated with metastasis and survival.














